Vasomotor Symptoms (Hot Flashes and Night Sweats): The Evidence on What Works
“I was told the hot flashes would pass in a couple of years. That was seven years ago, and they are still here.”
Hot flashes and night sweats are the defining symptom of the menopause transition and the most common one. Around half to three quarters of women experience them, and the clinical literature now sets their duration at a median of 7.4 years. That changes the treatment calculus. A symptom that persists for most of a decade is not a stage to wait out. It is a condition worth treating.
The treatment landscape has shifted in the last two years in a way that most recommendations have not caught up to. The first drug class built for hot flashes in decades, the neurokinin receptor antagonists, has now been through several meta-analyses. The evidence is decent and the trade-offs are specific. Here is what the research shows, option by option.
How Long Hot Flashes Actually Last
The single most useful number in the vasomotor literature comes from the SWAN cohort, a multiethnic observational study that followed 3,302 women across the transition. A 2015 analysis in JAMA Internal Medicine measured how long frequent vasomotor symptoms lasted. The median total duration was 7.4 years. Among women who reached the final menstrual period during follow-up, the symptoms went on a median of 4.5 years into postmenopause.
When the symptoms began mattered a great deal. Women who were premenopausal or early perimenopausal when they first reported frequent hot flashes had the longest spans, a median of over 11.8 years total and 9.4 years past the final menstrual period. Women who had already reached menopause before symptoms became frequent had the shortest span, a median of 3.4 years. If the onset is early, expect a long haul, not a brief stage.
Hormone Therapy Remains the Strongest Option
The research on hormone replacement therapy for vasomotor symptoms is consistent. A 2023 review in JAMA found that systemic estrogen, alone or with a progestogen, reduces the frequency of vasomotor symptoms by roughly 75 percent. Oral and transdermal estrogen have similar effects. For most women under 60, this is the benchmark every other treatment is measured against.
A 2025 network meta-analysis of 41 randomized trials and 14,743 women ranked synthetic conjugated estrogens as the most effective agent for reducing symptom frequency, with a mean difference of about 5.7 episodes versus placebo at 12 weeks. But hormone replacement therapy is not available to everyone. It is avoided in certain cancer histories and many women decline it. The nonhormonal evidence is where the alternatives matter.
SSRIs and the Placebo Problem
The classic nonhormonal alternative is paroxetine, the only SSRI the FDA approved for vasomotor symptoms, at 7.5 mg a day, far below the dose used for depression. The dose difference is real and side effects scale with dose. But the size of the true effect is in question.
A 2023 meta-analysis covering six paroxetine trials and 1,486 women found that 79 percent of the mean treatment response for hot flash frequency was accounted for by placebo. That is a large number. Much of what feels like improvement on an SSRI may be the same effect you would get from an inactive pill plus attention. It does not mean the drug does nothing. It means the drug effect is smaller than the reported gap suggests, and trials that did not account for placebo tend to overstate it.
A 2024 network review reached a related conclusion: the newer receptor agent beat paroxetine and the other nonhormonal options on frequency. The antidepressant route still has a role, especially in women who also manage mood, but pure hot flash relief was not its strength in the pooled data.
Gabapentin: It Works, With Side Effects
Gabapentin, an anticonvulsant, is a common alternative for women who cannot or will not take hormones. Its evidence is more solid than most people assume. A 2020 meta-analysis in Menopause pooled seven placebo controlled trials. Gabapentin produced a significantly larger drop across hot flash frequency, duration, and composite score. It also produced more adverse events, with an odds ratio of 1.58 for dizziness and 1.19 for unsteadiness versus placebo.
A broader 2020 systematic review in the American Journal of Obstetrics & Gynecology covered nineteen trials and 3,519 participants and confirmed gabapentin cut hot flash frequency at four and twelve weeks. The drug works. The understated catch is the dose dependent side effects.
The New Class: Receptor Antagonists Built for Hot Flashes
The most important development in the last two years is the first drug class designed for vasomotor symptoms specifically. Fezolinetant blocks the neurokinin-3 receptor upstream of the hot flash and does so with no hormonal action. It is a genuine nonhormonal option, and the evidence base has moved quickly.
A 2024 systematic review and network meta-analysis in Menopause compared this class against 27 hormone therapy regimens and the nonhormonal options. The central finding: the receptor antagonist did not differ significantly from any of the hormone therapy regimens on the 12 week frequency, and it significantly out-performed every nonhormonal agent evaluated, including paroxetine. An effective nonhormonal drug that matches hormones on frequency is the gap many women have been waiting for.
A 2024 meta-analysis in Climacteric pooled five randomized trials and 3,302 patients. Compared with placebo, fezolinetant reduced the daily frequency of vasomotor events by about 2.4 episodes at 12 weeks, did not differ on adverse events, and improved sleep disturbance and quality of life. A 2024 systematic review in European Journal of Obstetrics & Gynecology and Reproductive Biology across six studies and 3,301 patients reached a similar result.
| Treatment | Effect on hot flash frequency | Placebo context | Limits |
|---|---|---|---|
| Systemic estrogen (+ progestogen as needed) | About 75 percent reduction in frequency | Most effective agent tested | Avoided in some cancer histories; progestogen needed in most women |
| Fezolinetant (NK3 receptor antagonist) | About -2.4 episodes a day at 12 weeks; similar to hormones | No difference in adverse events | Not used in women with hormone-dependent cancer history |
| Elinzanetant (NK1/NK3 receptor antagonist) | Larger than paroxetine, comparable to fezolinetant | No difference in adverse events | Newest agent, fewer published analyses |
| Gabapentin / pregabalin | Frequency down about 2 to 3 episodes at 12 weeks | Placebo controlled | Dizziness and unsteadiness |
| Paroxetine 7.5 mg and other SSRIs | Reported reduction, but up to 79 percent was placebo | Mostly placebo driven | Dose side effects; the benefit is smaller than reported |
When Hormones Are Off the Table
For women with a hormone-dependent cancer history, the receptor class is usually closed because the trials excluded breast cancer patients. The remaining options are gabapentin for the heat sensation and an SSRI or SNRI antidepressant when mood is also a factor. A 2025 review in Current Opinion in Obstetrics & Gynecology went through the nonhormonal choices and reached a similar ladder: SSRIs, SNRIs, gabapentin, and the receptor antagonists are the active options.
A larger 2025 Bayesian network meta-analysis graded most products as safe relative to placebo, except one estradiol plus dydrogesterone product that showed more adverse events, with a risk ratio of 1.56. For cancer survivors, a 2025 review on breast cancer patients stressed that the receptor antagonist trials excluded that group, a gap that needs dedicated research.
What the Numbers Mean for You
The vasomotor literature has changed and the story most women still hear has not. Hot flashes run a median of about 7 years, sometimes more. That is a persistent condition, not a stage to survive. The answer is not automatically hormones. The receptor class now offers a hormone-class reduction, and the older nonhormonal drugs have real but smaller effects, with the antidepressant case carrying a large placebo floor.
- Do not wait through a seven year symptom. Ask for the full options, including the newest class.
- Hormone replacement therapy is still the strongest tool, cutting frequency by about 75 percent when available.
- If hormones are not right for you, the receptor antagonist has the best nonhormonal evidence.
- Gabapentin works, but the dose governs side effects.
- Read SSRI claims closely. Up to 79 percent of the reported benefit is placebo, so the real effect may be small.
The reassurance that hot flashes are only a short phase is wrong, and the options are growing while that story has not updated. The evidence supports treating vasomotor symptoms as what they are: a long, uncomfortable, and treatable part of the menopause transition.
Research notes:
- Duration of vasomotor symptoms (2015): SWAN cohort, 3,302 women. Median 7.4 years total; 4.5 years past the final menstrual period; over 11.8 years when onset was pre- or early perimenopausal. (DOI 10.1001/jamainternmed.2014.8063)
- 2023 JAMA review: Estrogen reduces frequency by about 75 percent; symptoms typically last over 7 years. (DOI 10.1001/jama.2022.24140)
- Network meta-analysis of all treatments (2025): 41 trials, 14,743 women; conjugated estrogens most effective for frequency; estradiol plus progestogen showed more adverse events (RR 1.56). (DOI 10.1016/j.ejogrb.2025.114552)
- Receptor antagonist vs hormones (2024): No difference from hormone therapy on frequency; beat all nonhormonal alternatives. (DOI 10.1097/GME.0000000000002281)
- Receptor antagonist meta-analysis (2024): Reduced frequency about 2.4 episodes a day at 12 weeks; no adverse event difference. (DOI 10.1080/13697137.2024.2334083)
- Receptor antagonist systematic review (2024): Six studies, 3,301 patients. (DOI 10.1016/j.ejogrb.2024.04.017)
- Elinzanetant comparison (2025): Above paroxetine and gabapentin on frequency. (DOI 10.1111/1471-0528.70213)
- Gabapentin meta-analysis (2020): Significant drop in hot flash frequency; more dizziness (OR 1.58). (DOI 10.1097/GME.0000000000001491)
- Gabapentin systematic review (2020): 19 trials, 3,519 participants. (DOI 10.1016/j.ajog.2019.12.011)
- Paroxetine placebo (2023): Six trials, 1,486 women; 79 percent of the response was placebo. (DOI 10.3389/fpsyt.2023.1204163)
- Paroxetine clinical review (2022): Only FDA approved nonhormonal agent; dose 7.5 mg per day. (DOI 10.2147/IJWH.S282396)
- Cancer patients (2025): Receptor class excluded breast cancer patients. (DOI 10.1080/17512433.2025.2573780)
Sources
Avis, N. E., et al. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine.
Crandall, C. J., et al. (2023). Management of Menopausal Symptoms: A Review. JAMA, 329(10).
Oliveira Amador, W. F., et al. (2025). Pharmacological treatments for menopausal vasomotor symptoms: a systematic review and network meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 312.
Morga, A., et al. (2024). Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for vasomotor symptoms. Menopause, 31(1).
Chavez, M. P., et al. (2024). Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis. Climacteric, 27(3).
El Naggar, A. A., et al. (2024). Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to menopause: a systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 297.
Wojciechowski, P., et al. (2026). Comparative efficacy of elinzanetant versus other nonhormonal pharmaceutical therapies for moderate to severe vasomotor symptoms: a network meta-analysis. BJOG: An International Journal of Obstetrics and Gynaecology.
Yoon, S. H., et al. (2020). Gabapentin for the treatment of hot flushes in menopause: a meta-analysis. Menopause, 27(4).
Shan, D., et al. (2020). Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. American Journal of Obstetrics & Gynecology, 222(6).
Rhodes, J. R., et al. (2023). Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis. Frontiers in Psychiatry, 14, 1204163.
David, P. S., et al. (2022). A clinical review on paroxetine and emerging therapies for the treatment of vasomotor symptoms. International Journal of Women’s Health, 14.
Fuhrman, J., et al. (2025). Practical considerations and emerging options for the management of vasomotor symptoms in breast cancer patients on endocrine therapy. Expert Review of Clinical Pharmacology, 18(10).